MiniMed Successfully Completes Independence from Medtronic, Heralding New Era in Diabetes Care

MiniMed Completes Separation from Medtronic

On October 15, 2026, MiniMed (Nasdaq: MMED) proudly announced the successful completion of its separation from Medtronic plc (NYSE: MDT). This landmark event signifies MiniMed's first day as an independent entity, strategically positioned to make impactful decisions in the diabetes care sector.

Que Dallara, CEO of MiniMed, expressed his gratitude towards Medtronic for their partnership and ongoing support throughout the separation process. He stated, "Today marks the completion of our separation from Medtronic and a significant milestone for MiniMed. We are grateful to Medtronic for its partnership and support in reaching this point. As an independent company, we have the freedom to make the decisions we believe are right for our business and the people we serve, and the responsibility to see those decisions through. Our focus now is to put that independence to work and continue advancing what is possible in diabetes care."

The separation process involved a significant exchange agreement: Medtronic accepted 55,032,401 of its ordinary shares in return for 252,813,348 shares of MiniMed’s common stock. As a result of this transaction, Medtronic no longer retains any equity stake in the newly independent MiniMed. The exchange was notably oversubscribed at a rate of 5.4x, highlighting the strong investor interest in MiniMed's future.

For investors and shareholders, the transition includes the crediting of newly issued MiniMed shares to accounts managed by the company’s transfer agent. Additionally, checks for fractional shares of MiniMed stock will be distributed once they have been aggregated and sold in the market, ensuring that all shareholders are compensated fairly and promptly.

About MiniMed

MiniMed has established itself as a global leader in insulin delivery, dedicated to enhancing therapies for individuals living with diabetes across 80 countries. Their comprehensive ecosystem encompasses state-of-the-art insulin delivery systems, continuous glucose monitors (CGMs), sophisticated algorithms, and an intuitive app experience, all designed to work seamlessly together.

For over four decades, MiniMed has been at the forefront of diabetes care innovation, always anticipating the needs of patients while reducing their daily burdens. The company's mission is clear: to enhance the quality of life for people with diabetes on a daily basis, making each day just a little bit easier and more manageable.

As MiniMed embarks on this new journey, their commitment to transformative diabetes care remains unwavering. The freedom to operate independently enables them to innovate boldly and respond adeptly to the evolving landscape of diabetes management, aiming to further advance the potential of diabetes care solutions in the years to come.

Future Prospects and Challenges

The completion of this separation marks just the beginning of MiniMed's journey as an independent company. They face the critical task of leveraging their newfound autonomy to drive innovation in diabetes management. Challenges ahead will include sustaining growth, expanding their reach, and continuing to adapt to the fast-paced advancements in diabetes technology.

Their focus on clinical effectiveness and user-friendly solutions will play a vital role in their ongoing success. With a growing prevalence of diabetes globally, MiniMed is well-positioned to meet the needs of patients through innovative approaches, ensuring that they remain a trusted ally for individuals managing their diabetes.

As stakeholders look ahead, MiniMed’s strategic vision and commitment to its mission will be pivotal in determining their success in reshaping diabetes care for the future.